The receiver operating characteristic (ROC) curve analysis was used to determine the area under the curve (AUC) and cut-off values of serum LC and ALC
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, has shown even more impressive weight loss data than tirzepatide in early trials
Cumulative loss ~40 lbs Months 7-12 (12mg): Additional 12-18 lbs
Semaglutide is another licensed weight loss injection in the UK and is the main alternative to liraglutide and tirzepatide
When I found MDWatch, it felt like the perfect solution
But I also think that there are places, such as with experimental treatments like with BPC-157, we probably need to press pause on at least until theres some actual human trials that trend towards FDA approval and keep things where they are today